source
- Latigo Biotherapeutics reports non-opioid drug cuts acute pain in Phase 2b trialLatigo Biotherapeutics announced that its experimental non-opioid analgesic demonstrated a reduction in acute pain in a Phase 2b clinical trial. The study results suggest the candidate may offer a…
- Trump administration revises 340B rebate pilot, sparking hospital backlashThe Health Resources and Services Administration announced a revision to the 340B drug pricing program’s rebate pilot, slated to begin on Jan 1, 2027. Under the new rules, participating manufactur…